# How many intentionally genomic DNA altered animals will be approved for consumption by the FDA on July 31, 2025? (QID: 38942)

- Type: numeric

- URL: https://www.metaculus.com/questions/38942/

- Classifier: health | strategic=False (score=0.00)

### SeenGuard

- enabled=True | lock_status=acquired

- run_filter: before=1 | skipped=0 | after=1

- debug_note=lock acquired

## Research (summary)

CALIBRATION GUIDANCE (auto-generated weekly):
BINARY CALIBRATION
- No resolved binary questions (with pre-resolution forecasts) yet.
- Advice: keep using base rates + small evidence-weighted updates; avoid big swings.

MULTIPLE-CHOICE CALIBRATION (Top-1)
- No resolved MCQ questions (with pre-resolution forecasts) yet.

NUMERIC CALIBRATION (PIT-lite + CRPS)
- No resolved numeric questions (with pre-resolution forecasts) yet.
- When numeric results exist, we’ll check p10/p50/p90 coverage and CRPS.

General takeaway: apply **small** nudges only where gaps are consistent with decent sample sizes (≥10).
— end calibration —

### Reference class & base rates
-   **FDA Approvals of Intentionally Genomic Altered (IGA) Animals for Food (2015-Present):** This is the most direct reference class. There have been three such approvals since the first in 2015.
    -   AquAdvantage Salmon (2015)
    -   GalSafe Pigs (2020)
    -   PRLR-SLICK Cattle (2024)
    -   This yields a base rate of 3 approvals over ~9 years, or approximately **0.33 approvals per year**. The interval between approvals has been 5 years and 4 years, suggesting a slow, multi-year process for each.
-   **FDA Center for Veterinary Medicine (CVM) Novel Product Approvals:** A broader class could include all novel animal drugs or biotechnologies approved by the CVM. This rate is higher but less specific, as it includes many products not intended for food or not involving genomic alteration. However, it reinforces the FDA's generally cautious and lengthy review timeline for any first-in-class product. The base rate here is highly variable but typically involves single-digit approvals of major novel products per year.
-   **Limitations:** The primary reference class (IGA animals for food) has an extremely small sample size (N=3), making any rate calculation highly uncertain. The first approval (salmon) was a pioneering case that faced unique political and regulatory hurdles, potentially skewing the average timeline.

### Recent developments (timeline bullets)
-   [2025-04-30] Article notes three IGA food animals have been approved to date. (→) — Confirms the current baseline count of 3, providing the most recent anchor point for the forecast.
-   [2025-02-27] FDA Q&A on AquAdvantage Salmon re-published. (→) — Indicates ongoing regulatory activity and communication but does not signal new approvals. It reinforces the established framework.
-   [2024-01-01] FDA approved Recombinate Biopharma's PRLR-SLICK cattle. (↑) — This was the third approval. It demonstrated continued momentum in the approval process and a shorter interval (4 years) than the first gap (5 years), suggesting a potential (slight) acceleration of the process.

### Mechanisms & drivers (causal levers)
-   **FDA Regulatory Process (Large, ↓):** The core mechanism is the FDA's review pathway, which treats IGAs as new animal drugs. This is an inherently slow, data-intensive, and multi-stage process involving safety assessments for the animal, the consumer, and the environment. It is the primary rate-limiting factor.
-   **Commercial & Societal Incentives (Large, ↑):** Strong economic drivers exist for traits like disease resistance (e.g., PRRS-resistant pigs), climate adaptation (heat-tolerant cattle), and improved animal welfare (hornless cattle). These incentives drive companies to invest in the lengthy R&D and regulatory process.
-   **Technological Advancement (Moderate, ↑):** Technologies like CRISPR/Cas9 make it faster and cheaper to create IGAs. However, this primarily affects the R&D phase, not the regulatory review timeline, which remains the bottleneck.
-   **Public & Political Opposition (Moderate, ↓):** Lingering consumer skepticism about "GMO" foods can create political pressure on the FDA, encouraging a cautious and deliberate approach. While opposition to recent approvals was less intense than for the AquAdvantage salmon, it remains a background factor.
-   **Risk of Ambiguous Resolution (Small, ↓):** The question becomes ambiguous if the FDA changes its regulatory framework. While there is industry pressure for this, major FDA policy shifts are slow and require extensive public comment. The probability of such a change occurring before July 31, 2025, is very low.

### Differences vs. the base rate (what’s unusual now)
-   **Accelerating Cadence (Slightly):** The time between the 1st and 2nd approval was ~5 years; between the 2nd and 3rd was ~4 years. This may suggest a slight "learning curve" effect within the FDA, but with N=3, this is weak evidence.
-   **Nature of Alterations:** The first approval (salmon) was transgenic. The most recent (cattle) introduced a naturally occurring allele via gene editing. The FDA may view such "nature-identical" edits as lower risk, potentially streamlining future, similar applications.
-   **Established Pipeline:** Unlike the 2010-2015 period, there is now a more publicly known pipeline of IGA animals in development (e.g., PRRS-resistant pigs by Genus PLC). This means there are known candidates, whereas before, the field was more speculative.
-   **Reduced Political Friction:** The intense political battle over the AquAdvantage salmon has not been repeated for subsequent approvals, suggesting the process, while still slow, is becoming more routine and less of a political lightning rod.

### Bayesian update sketch (for the statistician)
-   **Prior:** The base rate suggests a very low probability of a new approval within any given year. Starting from the known count of 3 in early 2024, a prior for the number of *additional* approvals by July 2025 would be heavily concentrated on 0, with a small probability on 1. (Equivalent n is low, perhaps 3-5, due to the small sample size of past approvals).
-   **Evidence mapping:**
    -   (↓, Large) The extremely short time horizon from the last known data point (April 2025) to the resolution date (July 31, 2025) is the most critical piece of evidence. FDA approval cycles are measured in years, not months.
    -   (↓, Moderate) There are no public announcements of any IGA food animal applications being in the final stages of review or open for public comment, which are necessary precursors to approval.
    -   (↑, Small) The approval of SLICK cattle in 2024 shows the process is active, not stalled. This slightly increases the chance of another approval *eventually*, but does little to change the odds within the next few months.
-   **Net effect:** The evidence overwhelmingly points toward the number remaining unchanged. The posterior distribution should be very tightly peaked at 3. The probability of the count being 4 or more is exceptionally low.

### Indicators to watch (leading signals; next weeks/months)
-   **UP indicators:**
    -   FDA announcement of a public comment period for a new IGA animal intended for food.
    -   A company (e.g., Genus PLC, Acceligen) press release stating they have formally submitted a complete application to the FDA for review.
    -   Leaked information or industry reports of an application reaching the final administrative review stage.
-   **DOWN indicators:**
    -   FDA statements emphasizing the rigor and length of the review process for any current or future applications.
    -   Negative news regarding the health or welfare of a leading IGA candidate animal (e.g., PRRS-pigs).
    -   Key companies announcing delays in their R&D or regulatory submission timelines.

### Caveats & pitfalls
-   **Definition of "variant":** The resolution criteria count "variants of rDNA constructs." It's possible a single company could get two slightly different constructs approved for the same animal/trait, which could resolve as +2. However, precedent suggests one approval per major product line.
-   **Information Asymmetry:** The precise status of any application is known only to the company and the FDA. A surprise approval is possible, though highly improbable given typical FDA communication protocols (e.g., public comment periods).
-   **Ambiguity Clause:** While the risk of the regulatory framework changing is low, it is not zero. This would render the question ambiguous and is a key tail risk to monitor.
-   **Non-Food Approvals:** An IGA animal could be approved for non-food purposes (e.g., biopharma), which would not count for this question but could be confused with a food approval in news headlines.

**Final Research Summary:** The current number of approved IGA animals for food is three. Given the multi-year FDA approval timeline and the short period until resolution, it is extremely unlikely that another animal will complete this process by July 31, 2025. The forecast should be strongly anchored at 3.

Market snapshot debug:
- Metaculus: no open binary results in response
- Manifold: no open binary results in response

### Sources
- FDA poised to approve more genetically engineered food animals (geneticliteracyproject.org) — https://geneticliteracyproject.org/2025/04/30/fda-poised-to-approve-more-genetically-engineered-food-animals/
- Q&A on FDA's Approval of AquAdvantage Salmon (www.fda.gov) — https://www.fda.gov/animal-veterinary/animal-biotechnology/qa-fdas-approval-aquadvantage-salmon
- An HSUS Report: Welfare Issues with Genetic Engineering and Cloning of Farm Animals (www.humanesociety.org) — https://www.humanesociety.org/sites/default/files/docs/hsus-report-welfare-issues-genetic-engineering-and-cloning-farm-animals.pdf
- GMO salmon makes history with FDA approval (www.cbs19.tv) — https://www.cbs19.tv/article/news/health/gmo-salmon-makes-history-with-fda-approval/501-289892185

### Research (debug)

- source=GoogleGrounding | llm=google/gemini-2.5-pro | cached=0 | n_raw=11 | n_kept=4 | cost=$0.023235

- query: format; metac_closes_in_period; info; post_id; question_id; variants of rDNA constructs in intentionally genomic DNA altered animals; animal drugs; HSUS Report; The AquAdvantage; AquAdvantage Salmon; 2006; 2025; 2018; 2019

### GTMC1 (debug)

- strategic_class=False | strategic_score=0.00 | source=llm

- gtmc1_active=False | qtype=numeric | t_ms=0

- actors_parsed=0

- exceedance_ge_50=None | coalition_rate=None | median=None | dispersion=None

### Ensemble (model outputs)

- OpenRouter-Default: ok=True t_ms=11452 P10=31.000, P50=2025.000, P90=1.000

- Claude-3.7-Sonnet (OR): ok=True t_ms=22330 P10=31.000, P50=2025.000, P90=1.000

- Gemini: ok=True t_ms=64649 P10=1.000, P50=1.000, P90=2015.000

- Grok: ok=False t_ms=229



### Per-model (raw + usage/cost)

#### OpenRouter-Default

- ok=True | t_ms=11452 | tokens: prompt=3755, completion=609, total=4364 | cost=$0.015477

```md

To forecast the number of intentionally genomic DNA altered animals approved for consumption by the FDA by July 31, 2025, we will follow the structured Bayesian reasoning approach:

1. **Base Rate (Prior) Selection**
   - **Base Rate:** The most direct reference class is FDA approvals of intentionally genomic altered (IGA) animals for food since 2015. There have been three approvals: AquAdvantage Salmon (2015), GalSafe Pigs (2020), and PRLR-SLICK Cattle (2024). This gives a base rate of approximately 0.33 approvals per year.
   - **Mean/Median and Variance:** The mean is approximately 0.33 approvals per year, with a high variance due to the small sample size (N=3).

2. **Comparison to Base Case**
   - **Similarities:** The regulatory process remains slow and deliberate, with approvals typically taking multiple years.
   - **Differences:** The interval between approvals has decreased slightly (5 years to 4 years), suggesting a potential acceleration. However, the sample size is too small to draw strong conclusions.

3. **Evidence Evaluation (Likelihoods)**
   - **Short Time Horizon (↓, Large):** The time from the last known approval (January 2024) to the resolution date (July 31, 2025) is very short for the FDA's typical multi-year review process.
   - **No Public Announcements (↓, Moderate):** There are no known applications in the final stages of review, which are necessary for approval.
   - **Recent Approval (↑, Small):** The approval of PRLR-SLICK cattle in 2024 indicates the process is active, but this does not significantly increase the likelihood of another approval by July 2025.

4. **Bayesian Updating (Posterior Distribution)**
   - **Prior:** Concentrated on 0 additional approvals by July 2025.
   - **Likelihood:** Strong evidence against a new approval due to the short timeline and lack of public announcements.
   - **Posterior:** The distribution remains tightly peaked at 3 total approvals, with a very low probability of reaching 4 or more.

5. **Red Team Thinking**
   - **Overconfidence Check:** Considered the possibility of a surprise approval, but the lack of public indicators makes this unlikely.
   - **Tail Risks:** The main risk is a regulatory framework change, but this is deemed very low probability.
   - **Alternative Forecast:** An alternative scenario with 4 approvals is possible but highly improbable given current evidence.

6. **Final Percentiles**
   - Given the analysis, the forecast is strongly anchored at 3 approvals, with very low probability for 4 or more.
   - Percentiles reflect the high confidence in no additional approvals by the resolution date.

P10: 3  
P20: 3  
P40: 3  
P60: 3  
P80: 3  
P90: 3

```

#### Claude-3.7-Sonnet (OR)

- ok=True | t_ms=22330 | tokens: prompt=4261, completion=1160, total=5421 | cost=$0.030183

```md

# Forecast: FDA-Approved Genomic Altered Animals for Consumption by July 31, 2025

## 1. Base Rate (Prior) Selection

For this forecast, I'll use the historical rate of FDA approvals for intentionally genomic altered (IGA) animals for food consumption as my primary reference class:

- To date, there have been 3 approvals:
  - AquAdvantage Salmon (2015)
  - GalSafe Pigs (2020)
  - PRLR-SLICK Cattle (2024)

This gives us a base rate of 3 approvals over approximately 9 years, or about 0.33 approvals per year. The intervals between approvals (5 years, then 4 years) suggest a slow, multi-year process for each approval.

Given that we have 3 approved animals as of April 2025 (per the most recent data point), and we're forecasting for July 31, 2025, my prior distribution is heavily concentrated at 3, with small probability mass at 4, and negligible probability at higher values.

## 2. Comparison to Base Case

**Similarities to base case:**
- The FDA's regulatory framework for IGA animals remains unchanged
- The approval process continues to be lengthy and rigorous
- Public and political attitudes toward genetically modified food animals remain cautious

**Differences from base case:**
- Slightly accelerating cadence: The gap between approvals decreased from 5 years to 4 years
- Established precedent: The FDA now has experience evaluating these applications
- Short time horizon: We're only looking at ~3 months from the latest data point to resolution
- Known pipeline: Unlike the early days, there are now publicly known IGA animals in development

## 3. Evidence Evaluation (Likelihoods)

**Evidence for no change (remaining at 3):**
- The extremely short time horizon (April to July 2025) makes a new approval highly unlikely given the multi-year FDA review process (very strong evidence, likelihood ratio ~20:1 favoring no change)
- No public announcements of any IGA food animal applications in final stages of review or open for public comment, which are necessary precursors to approval (moderate evidence, likelihood ratio ~5:1 favoring no change)

**Evidence for an increase (to 4 or more):**
- The approval of SLICK cattle in 2024 shows the process is active, not stalled (weak evidence, likelihood ratio ~1.2:1 favoring an increase)
- Potential for "surprise" approvals that weren't publicly known to be in final stages (very weak evidence, likelihood ratio ~1.05:1 favoring an increase)

## 4. Bayesian Updating (Posterior Distribution)

Starting with my prior heavily concentrated at 3:
- Prior: P(3) = 0.90, P(4) = 0.09, P(5+) = 0.01

After updating on the short time horizon evidence:
- Likelihood ratio: ~20:1 favoring no change
- Intermediate posterior: P(3) ≈ 0.995, P(4) ≈ 0.005, P(5+) ≈ 0.0001

After updating on the lack of public announcements:
- Likelihood ratio: ~5:1 favoring no change
- Posterior: P(3) ≈ 0.998, P(4) ≈ 0.002, P(5+) ≈ 0.00005

The posterior distribution is now extremely concentrated at 3, with only a tiny probability of 4 or more approvals by July 31, 2025.

## 5. Red Team Thinking

**Potential blind spots:**
- Information asymmetry: The FDA might have applications in advanced stages not publicly known
- Accelerating process: The FDA might be streamlining its review process more than historical data suggests
- Multiple variants: A single company could get multiple variants approved simultaneously

**Alternative forecast:**
A reasonable alternative would place more weight on the possibility of a surprise approval, perhaps arguing that the FDA has been working behind the scenes on applications that are nearly complete. This would suggest a posterior more like P(3) = 0.95, P(4) = 0.04, P(5) = 0.01.

**Rebuttal:**
While possible, this alternative doesn't account for the FDA's consistent pattern of public disclosure before approvals, including public comment periods. The extremely short timeframe until July 31, 2025, makes it virtually impossible for an application not already in the final stages to be approved in time.

**Adjustment:**
I'll slightly increase the probability of 4 approvals to account for the small possibility of a surprise approval or an application already in final stages that hasn't been publicly disclosed.

## 6. Final Percentiles

P10: 3
P20: 3
P40: 3
P60: 3
P80: 3
P90: 3

```

#### Gemini

- ok=True | t_ms=64649 | tokens: prompt=4077, completion=1729, total=10891 | cost=$0.022386

```md

### 1. Base Rate (Prior) Selection

The target variable is the total number of intentionally genomic DNA altered (IGA) animals approved for consumption by the FDA on a specific date. The most appropriate reference class is the history of these specific approvals.

*   **Reference Class**: FDA approvals of IGA animals for human consumption.
*   **Historical Data**:
    1.  AquAdvantage Salmon (November 2015)
    2.  GalSafe Pigs (December 2020)
    3.  PRLR-SLICK Cattle (January 2024)
*   **Current Count**: As of the latest information in the research report (April 30, 2025), the number of approved animals is 3.
*   **Base Rate Calculation**: There have been 3 approvals in approximately 9 years (late 2015 to early 2024), giving a rate of roughly 0.33 approvals per year, or one approval every 3-5 years.
*   **Prior Distribution**: The question asks for the total count on July 31, 2025. Since the count is known to be 3 as of April 30, 2025, the forecast is about the number of *new* approvals in the 3-month window of May, June, and July 2025. Using the base rate of 0.33 approvals/year, the expected number of approvals in a 3-month (0.25 year) period is 0.33 * 0.25 ≈ 0.08. A Poisson distribution with λ=0.08 would suggest:
    *   P(0 new approvals) ≈ 92%
    *   P(1 new approval) ≈ 7.5%
    *   P(2+ new approvals) < 0.5%
    My prior distribution for the total count is therefore heavily concentrated at 3, with a small probability of it becoming 4.

### 2. Comparison to Base Case

*   **Similarities**: The fundamental regulatory process remains unchanged. The FDA's Center for Veterinary Medicine (CVM) treats IGAs as new animal drugs, a process known for being slow, deliberate, and data-intensive. This core mechanism, which drove the slow historical rate, is still in place.
*   **Differences**: While the cadence of approvals may be slightly accelerating (5 years between #1 and #2, vs. ~3 years between #2 and #3), this is based on a tiny sample size. The key difference for this forecast is the extremely short time horizon. We are not forecasting over a multi-year period where the base rate would be most applicable, but over a specific, imminent 3-month window.

### 3. Evidence Evaluation (Likelihoods)

The analysis hinges on the probability of a new approval occurring between May 1 and July 31, 2025.

*   **Evidence 1: Extremely Short Time Horizon (3 months)**. This is the most powerful piece of evidence. The FDA's approval process for novel products like these typically takes many years from submission to final approval. A final decision being reached in a 3-month window is extraordinarily unlikely. This evidence makes an outcome of 3 (no change) far more likely than an outcome of 4 or more. (Likelihood Ratio P(Evidence|3) / P(Evidence|4) is very high, perhaps >50:1).
*   **Evidence 2: Lack of Public Signals**. Major novel approvals from the FDA are usually preceded by public announcements, such as the opening of a public comment period on a draft environmental assessment or a finding of no significant impact. The research report indicates no such announcements have been made for any new IGA food animal. The absence of these leading indicators further reduces the probability of an approval within the next three months. This strongly supports the count remaining at 3.
*   **Evidence 3: Known Pipeline (e.g., PRRS-resistant pigs)**. Companies like Genus PLC have products in the regulatory pipeline. This confirms that there are candidates for future approval. However, this only establishes the *possibility* of a future approval, it does not provide evidence for the *timing*. Without specific announcements from the FDA or the company about being in the final stage of review, this evidence has little impact on the forecast for the next 3 months.

### 4. Bayesian Updating (Posterior Distribution)

*   **Prior**: P(Total=3) ≈ 92%, P(Total=4) ≈ 7.5%.
*   **Likelihoods**: The evidence (extremely short 3-month window, no public signals) is highly consistent with the outcome remaining 3 and highly inconsistent with the outcome becoming 4.
*   **Update**:
    Posterior Odds(4 vs 3) = Prior Odds(4 vs 3) × Likelihood Ratio
    The Likelihood Ratio is very small (heavily favoring 3).
    The prior already strongly favored 3. The evidence strengthens this belief immensely.
*   **Posterior Distribution**: The updated posterior probability for the count remaining at 3 is now extremely high, likely in the range of 97-99%. The probability of the count increasing to 4 is a tail risk, representing a truly unexpected, rapid, and un-telegraphed approval. The probability of the count increasing to 5 or more is negligible. My final distribution is approximately P(3) = 97%, P(4) = 3%.

### 5. Red Team Thinking

*   **Alternative Scenario: A Surprise Approval**. Could the FDA rush an approval? It's possible if there were immense political pressure or a national emergency related to food supply, but neither condition is present. It's also possible that a very low-risk application (e.g., a simple gene edit mirroring a naturally occurring allele, like the SLICK cattle) could move through an expedited, non-public process. This is the primary argument for why the probability of the count being 4 is not absolute zero.
*   **Rebuttal**: The FDA's institutional inertia and commitment to its established, public-facing process for novel approvals make such a surprise highly improbable. The precedent set by the first three approvals is one of caution and long timelines.
*   **Risk of Decrease**: An approval could theoretically be revoked, but this is an exceptionally rare event and there is no indication of any issues with the three existing approvals. The probability of the count decreasing is negligible.
*   **Adjustment**: My posterior of P(3) ≈ 97% already accounts for the small chance of a surprise. It reflects very high confidence, which is warranted by the short time frame and lack of signals, while not being absolute 100% certain. The percentiles should reflect this strong concentration at 3.

### 6. Final Percentiles

My posterior distribution is P(3) = 97%, P(4) = 3%.
The cumulative distribution function (CDF) is:
*   CDF(X < 3) = 0
*   CDF(X ≤ 3) = 0.97
*   CDF(X ≤ 4) = 1.00

To find the percentiles:
*   The 10th percentile is the value `v` where CDF(v) ≥ 0.10. Since CDF(3) is 0.97, the 10th percentile is 3.
*   This logic applies for the 20th, 40th, 60th, 80th, and 90th percentiles, as they are all less than 97. The value remains 3 until we cross the 97th percentile.

P10: 3
P20: 3
P40: 3
P60: 3
P80: 3
P90: 3

```

#### Grok

- ok=False | t_ms=229 | tokens: prompt=0, completion=0, total=0 | cost=$0.000000

- error=HTTP 429: Your team 0101076a-72f1-4f25-a038-b346d74bbc8d has either used all available credits or reached its monthly spending limit. To continue making API requests, please purchase more credits or raise your spending limit.

### Aggregation (BMC)

- final_quantiles: P10=-996.4721320429649, P50=18.809621896541234, P90=1047.7151687493895

- bmc_summary={"mean": 24.78021068498928, "p10": -996.4721320429649, "p50": 18.809621896541234, "p90": 1047.7151687493895}